PLoS ONE (Jan 2017)

Investigating the validity of the DN4 in a consecutive population of patients with chronic pain.

  • Hans Timmerman,
  • Monique A H Steegers,
  • Frank J P M Huygen,
  • Jelle J Goeman,
  • Nick T van Dasselaar,
  • Marcel J Schenkels,
  • Oliver H G Wilder-Smith,
  • André P Wolff,
  • Kris C P Vissers

DOI
https://doi.org/10.1371/journal.pone.0187961
Journal volume & issue
Vol. 12, no. 11
p. e0187961

Abstract

Read online

Neuropathic pain is clinically described as pain caused by a lesion or disease of the somatosensory nervous system. The aim of this study was to assess the validity of the Dutch version of the DN4, in a cross-sectional multicentre design, as a screening tool for detecting a neuropathic pain component in a large consecutive, not pre-stratified on basis of the target outcome, population of patients with chronic pain. Patients' pain was classified by two independent (pain-)physicians as the gold standard. The analysis was initially performed on the outcomes of those patients (n = 228 out of 291) in whom both physicians agreed in their pain classification. Compared to the gold standard the DN4 had a sensitivity of 75% and specificity of 76%. The DN4-symptoms (seven interview items) solely resulted in a sensitivity of 70% and a specificity of 67%. For the DN4-signs (three examination items) it was respectively 75% and 75%. In conclusion, because it seems that the DN4 helps to identify a neuropathic pain component in a consecutive population of patients with chronic pain in a moderate way, a comprehensive (physical-) examination by the physician is still obligate.